26 research outputs found
Gene therapy for Wiskott-Aldrich syndrome-long-term efficacy and genotoxicity
No full textWiskott-Aldrich syndrome (WAS) is characterized by microthrombocytopenia, immunodeficiency, autoimmunity, and susceptibility to malignancies. In our hematopoietic stem cell gene therapy (GT) trial using a γ-retroviral vector, 9 of 10 patients showed sustained engraftment and correction of WAS protein (WASP) expression in lymphoid and myeloid cells and platelets. GT resulted in partial or complete resolution of immunodeficiency, autoimmunity, and bleeding diathesis. Analysis of retroviral insertion sites revealed 140,000 unambiguous integration sites and a polyclonal pattern of hematopoiesis in all patients early after GT. Seven patients developed acute leukemia [one acute myeloid leukemia (AML), four T cell acute lymphoblastic leukemia (T-ALL), and two primary T-ALL with secondary AML associated with a dominant clone with vector integration at the LMO2 (six T-ALL), MDS1 (two AML), or MN1 (one AML) locus]. Cytogenetic analysis revealed additional genetic alterations such as chromosomal translocations. This study shows that hematopoietic stem cell GT for WAS is feasible and effective, but the use of γ-retroviral vectors is associated with a substantial risk of leukemogenesis.Abel U, 2007, PLOS ONE, V2, DOI 10.1371-journal.pone.0000570; Aiuti A, 2002, SCIENCE, V296, P2410, DOI 10.1126-science.1070104; Aiuti A, 2009, NEW ENGL J MED, V360, P447, DOI 10.1056-NEJMoa0805817; Aiuti A, 2013, SCIENCE, V341, P865, DOI 10.1126-science.1233151; Banerjee PP, 2007, J EXP MED, V204, P2305, DOI 10.1084-jem.20061893; Baum C, 2007, CURR OPIN HEMATOL, V14, P337, DOI 10.1097-MOH.0b013e3281900f01; BENE MC, 1995, LEUKEMIA, V9, P1783; Bosticardo M, 2009, BLOOD, V113, P6288, DOI 10.1182-blood-2008-12-115253; Bouma G, 2009, IMMUNOBIOLOGY, V214, P778, DOI 10.1016-j.imbio.2009.06.009; Boztug K, 2010, NEW ENGL J MED, V363, P1918, DOI 10.1056-NEJMoa1003548; Boztug K, 2008, CLIN GENET, V74, P68, DOI 10.1111-j.1399-0004.2008.01019.x; Boztug K, 2006, CURR OPIN MOL THER, V8, P390; Carella C, 2007, LEUKEMIA, V21, P1679, DOI 10.1038-sj.leu.2404778; Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126-science.288.5466.669; Charrier S, 2007, GENE THER, V14, P415, DOI 10.1038-sj.gt.3302863; Dave UP, 2004, SCIENCE, V303, P333, DOI 10.1126-science.1091667; Deichmann A, 2011, MOL THER, V19, P2031, DOI 10.1038-mt.2011.178; Deichmann A, 2007, J CLIN INVEST, V117, P2225, DOI 10.1172-JCI31659; De Rijck J, 2013, CELL REP, V5, P886, DOI 10.1016-j.celrep.2013.09.040; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016-0092-8674(94)90528-2; Dewey Ricardo A, 2006, Exp Hematol, V34, P1161, DOI 10.1016-j.exphem.2006.04.021; Fischer A, 2010, NAT IMMUNOL, V11, P457, DOI 10.1038-ni0610-457; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038-nrc1299; Hacein-Bey-Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126-science.1088547; Hacein-Bey-Abina S, 2003, NEW ENGL J MED, V348, P255, DOI 10.1056-NEJM200301163480314; Hacein-Bey-Abina S, 2010, NEW ENGL J MED, V363, P355, DOI 10.1056-NEJMoa1000164; Hacein-Bey-Abina S, 2008, J CLIN INVEST, V118, P3132, DOI [10.1172-JCI35700, 10.1172-JC135700]; Hacein-Bey-Abina S, 2002, NEW ENGL J MED, V346, P1185, DOI 10.1056-NEJMoa012616; Howe SJ, 2008, J CLIN INVEST, V118, P3143, DOI 10.1172-JCI35798; Imai K, 2004, BLOOD, V103, P456, DOI 10.1182-blood-2003-05-1480; Kay MA, 2011, NAT REV GENET, V12, P316, DOI 10.1038-nrg2971; Kent WJ, 2002, GENOME RES, V12, P656, DOI [10.1101-gr.229202, 10.1101-gr.229202. Article published online before March 2002]; Klein C, 2000, J EXP MED, V191, P1699, DOI 10.1084-jem.191.10.1699; McCormack MP, 2004, NEW ENGL J MED, V350, P913, DOI 10.1056-NEJMra032207; Mohty M, 2011, LEUKEMIA, V25, P1, DOI 10.1038-leu.2010.224; Moratto D, 2011, BLOOD, V118, P1675, DOI 10.1182-blood-2010-11-319376; Nagel S, 2010, LEUKEMIA RES, V34, P521, DOI 10.1016-j.leukres.2009.06.020; Notarangelo LD, 2008, CURR OPIN HEMATOL, V15, P30; Orange JS, 2002, P NATL ACAD SCI USA, V99, P11351, DOI 10.1073-pnas.162376099; Ott MG, 2006, NAT MED, V12, P401, DOI 10.1038-nm1393; Pannetier C., 1997, ANTIGEN T CELL RECEP; PANNETIER C, 1995, IMMUNOL TODAY, V16, P176, DOI 10.1016-0167-5699(95)80117-0; Paruzynski A, 2010, NAT PROTOC, V5, P1379, DOI 10.1038-nprot.2010.87; Puck JM, 2006, NEW ENGL J MED, V355, P1759, DOI 10.1056-NEJMp068209; Schlegelberger B., 2002, FISH TECHNOLOGY, P442; Schlegelberger B., 1999, CYTOGENETICS, P151; Schmidt Manfred, 2007, Nat Methods, V4, P1051, DOI 10.1038-nmeth1103; Schrappe M, 2011, BLOOD, V118, P2077, DOI 10.1182-blood-2011-03-338707; Schwarzwaelder K, 2007, J CLIN INVEST, V117, P2241, DOI 10.1172-JCI31661; Shannon C. E., 1948, MATH THEORY COMMUNIC; SIMPSON EH, 1949, NATURE, V163, P688, DOI 10.1038-163688a0; Stein S, 2010, NAT MED, V16, P198, DOI 10.1038-nm.2088; Stone BD, 2004, NEW ENGL J MED, V350, P2526; SULLIVAN KE, 1994, J PEDIATR, V125, P876, DOI 10.1016-S0022-3476(05)82002-5; Thrasher AJ, 2002, NAT REV IMMUNOL, V2, P635, DOI 10.1038-nri884; Thrasher AJ, 2005, BLOOD, V105, P4255, DOI 10.1182-blood-2004-12-4837; Wada T, 2005, BLOOD, V106, P3895, DOI 10.1182-blood-2005-06-2336; Willatt L., 2009, HUM GENET, V126, P603; ZHU QL, 1995, BLOOD, V86, P37977171
Inherited DOCK2 Deficiency in Patients with Early-Onset Invasive Infections
No full textFull author list omitted for brevity. For the full list of authors, see article.Background Combined immunodeficiencies are marked by inborn errors of T-cell immunity in which the T cells that are present are quantitatively or functionally deficient. Impaired humoral immunity is also common. Patients have severe infections, autoimmunity, or both. The specific molecular, cellular, and clinical features of many types of combined immunodeficiencies remain unknown. Methods We performed genetic and cellular immunologic studies involving five unrelated children with early-onset invasive bacterial and viral infections, lymphopenia, and defective T-cell, B-cell, and natural killer (NK)-cell responses. Two patients died early in childhood; after allogeneic hematopoietic stem-cell transplantation, the other three had normalization of T-cell function and clinical improvement. Results We identified biallelic mutations in the dedicator of cytokinesis 2 gene (DOCK2) in these five patients. RAC1 activation was impaired in the T cells. Chemokine-induced migration and actin polymerization were defective in the T cells, B cells, and NK cells. NK-cell degranulation was also affected. Interferon-alpha and interferon-lambda production by peripheral-blood mononuclear cells was diminished after viral infection. Moreover, in DOCK2-deficient fibroblasts, viral replication was increased and virus-induced cell death was enhanced; these conditions were normalized by treatment with interferon alfa-2b or after expression of wild-type DOCK2. Conclusions Autosomal recessive DOCK2 deficiency is a new mendelian disorder with pleiotropic defects of hematopoietic and nonhematopoietic immunity. Children with clinical features of combined immunodeficiencies, especially with early-onset, invasive infections, may have this condition. (Supported by the National Institutes of Health and others.)
Author correction: Gain-of-function variants in SYK cause immune dysregulation and systemic inflammation in humans and mice
No full textAuthor Correction: Gain-of-function variants in SYK cause immune dysregulation and systemic inflammation in humans and mice (Nature Genetics, (2021), 53, 4, (500-510), 10.1038/s41588-021-00803-4)
No full text\ua9 The Author(s), under exclusive licence to Springer Nature America, Inc. 2022. n the version of this article initially published, there was a numbering error in the affiliation for Christoph Klein. The author’s proper affiliation is 30, Department of Pediatrics, Dr. von Hauner Children’s Hospital, University Hospital, Ludwig Maximilian University Munich, Munich, Germany, and not Newcastle University, UK. The change has been made to the online version of the article
Current recommendations for clinical surveillance and genetic testing in rhabdoid tumor predisposition: a report from the SIOPE Host Genome Working Group
No full textThe rhabdoid tumor (RT) predisposition syndromes 1 and 2 (RTPS1 and 2) are rare genetic conditions rendering young children vulnerable to an increased risk of RT, malignant neoplasms affecting the kidney, miscellaneous soft-part tissues, the liver and the central nervous system (Atypical Teratoid Rhabdoid Tumors, ATRT). Both, RTPS1&2 are due to pathogenic variants (PV) in genes encoding constituents of the BAF chromatin remodeling complex, i.e. SMARCB1 (RTPS1) and SMARCA4 (RTPS2). In contrast to other genetic disorders related to PVs in SMARCB1 and SMARCA4 such as Coffin-Siris Syndrome, RTPS1&2 are characterized by a predominance of truncating PVs, terminating transcription thus explaining a specific cancer risk. The penetrance of RTPS1 early in life is high and associated with a poor survival. However, few unaffected carriers may be encountered. Beyond RT, the tumor spectrum may be larger than initially suspected, and cancer surveillance offered to unaffected carriers (siblings or parents) and long-term survivors of RT is still a matter of discussion. RTPS2 exposes female carriers to an ill-defined risk of small cell carcinoma of the ovaries, hypercalcemic type (SCCOHT), which may appear in prepubertal females. RT surveillance protocols for these rare families have not been established. To address unresolved issues in the care of individuals with RTPS and to propose appropriate surveillance guidelines in childhood, the SIOPe Host Genome working group invited pediatric oncologists and geneticists to contribute to an expert meeting. The current manuscript summarizes conclusions of the panel discussion, including consented statements as well as non-evidence-based proposals for validation in the future. © 2021, The Author(s)
Gain-of-function variants in <em>SYK </em>cause immune dysregulation and systemic inflammation in humans and mice
No full text\ua9 2021, The Author(s), under exclusive licence to Springer Nature America, Inc.Spleen tyrosine kinase (SYK) is a critical immune signaling molecule and therapeutic target. We identified damaging monoallelic SYK variants in six patients with immune deficiency, multi-organ inflammatory disease such as colitis, arthritis and dermatitis, and diffuse large B cell lymphomas. The SYK variants increased phosphorylation and enhanced downstream signaling, indicating gain of function. A knock-in (SYK-Ser544Tyr) mouse model of a patient variant (p.Ser550Tyr) recapitulated aspects of the human disease that could be partially treated with a SYK inhibitor or transplantation of bone marrow from wild-type mice. Our studies demonstrate that SYK gain-of-function variants result in a potentially treatable form of inflammatory disease
Outcomes and Treatment Strategies for Autoimmunity and Hyperinflammation in Patients with RAG Deficiency
No full textBackground: Although autoimmunity and hyperinflammation secondary to recombination activating gene (RAG) deficiency have been associated with delayed diagnosis and even death, our current understanding is limited primarily to small case series. Objective: Understand the frequency, severity, and treatment responsiveness of autoimmunity and hyperinflammation in RAG deficiency. Methods: In reviewing the literature and our own database, we identified 85 patients with RAG deficiency, reported between 2001 and 2016, and compiled the largest case series to date of 63 patients with prominent autoimmune and/or hyperinflammatory pathology. Results: Diagnosis of RAG deficiency was delayed a median of 5 years from the first clinical signs of immune dysregulation. Most patients (55.6%) presented with more than 1 autoimmune or hyperinflammatory complication, with the most common etiologies being cytopenias (84.1%), granulomas (23.8%), and inflammatory skin disorders (19.0%). Infections, including live viral vaccinations, closely preceded the onset of autoimmunity in 28.6% of cases. Autoimmune cytopenias had early onset (median, 1.9, 2.1, and 2.6 years for autoimmune hemolytic anemia, immune thrombocytopenia, and autoimmune neutropenia, respectively) and were refractory to intravenous immunoglobulin, steroids, and rituximab in most cases (64.7%, 73.7%, and 71.4% for autoimmune hemolytic anemia, immune thrombocytopenia, and autoimmune neutropenia, respectively). Evans syndrome specifically was associated with lack of response to first-line therapy. Treatment-refractory autoimmunity/hyperinflammation prompted hematopoietic stem cell transplantation in 20 patients. Conclusions: Autoimmunity/hyperinflammation can be a presenting sign of RAG deficiency and should prompt further evaluation. Multilineage cytopenias are often refractory to immunosuppressive treatment and may require hematopoietic cell transplantation for definitive management. © 2019 The Author
Autoantibodies against type I IFNs in humans with alternative NF-κB pathway deficiency
No full text\ua9 2023, The Author(s). Patients with autoimmune polyendocrinopathy syndrome type 1 (APS-1) caused by autosomal recessive AIRE deficiency produce autoantibodies that neutralize type I interferons (IFNs)1,2, conferring a predisposition to life-threatening COVID-19 pneumonia3. Here we report that patients with autosomal recessive NIK or RELB deficiency, or a specific type of autosomal-dominant NF-κB2 deficiency, also have neutralizing autoantibodies against type I IFNs and are at higher risk of getting life-threatening COVID-19 pneumonia. In patients with autosomal-dominant NF-κB2 deficiency, these autoantibodies are found only in individuals who are heterozygous for variants associated with both transcription (p52 activity) loss of function (LOF) due to impaired p100 processing to generate p52, and regulatory (IκBδ activity) gain of function (GOF) due to the accumulation of unprocessed p100, therefore increasing the inhibitory activity of IκBδ (hereafter, p52LOF/IκBδGOF). By contrast, neutralizing autoantibodies against type I IFNs are not found in individuals who are heterozygous for NFKB2 variants causing haploinsufficiency of p100 and p52 (hereafter, p52LOF/IκBδLOF) or gain-of-function of p52 (hereafter, p52GOF/IκBδLOF). In contrast to patients with APS-1, patients with disorders of NIK, RELB or NF-κB2 have very few tissue-specific autoantibodies. However, their thymuses have an abnormal structure, with few AIRE-expressing medullary thymic epithelial cells. Human inborn errors of the alternative NF-κB pathway impair the development of AIRE-expressing medullary thymic epithelial cells, thereby underlying the production of autoantibodies against type I IFNs and predisposition to viral diseases
The Human Phenotype Ontology in 2024: phenotypes around the world
No full text\ua9 The Author(s) 2023. Published by Oxford University Press on behalf of Nucleic Acids Research. The Human Phenotype Ontology (HPO) is a widely used resource that comprehensively organizes and defines the phenotypic features of human disease, enabling computational inference and supporting genomic and phenotypic analyses through semantic similarity and machine learning algorithms. The HPO has widespread applications in clinical diagnostics and translational research, including genomic diagnostics, gene-disease discovery, and cohort analytics. In recent years, groups around the world have developed translations of the HPO from English to other languages, and the HPO browser has been internationalized, allowing users to view HPO term labels and in many cases synonyms and definitions in ten languages in addition to English. Since our last report, a total of 2239 new HPO terms and 49235 new HPO annotations were developed, many in collaboration with external groups in the fields of psychiatry, arthrogryposis, immunology and cardiology. The Medical Action Ontology (MAxO) is a new effort to model treatments and other measures taken for clinical management. Finally, the HPO consortium is contributing to efforts to integrate the HPO and the GA4GH Phenopacket Schema into electronic health records (EHRs) with the goal of more standardized and computable integration of rare disease data in EHRs
